News | MRI Breast | August 06, 2021

Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy

Receiver operator characteristics curve for the optimal response classifiers, optimized for maximum F1-Score. The AUCs for each classifier are reported in the legend. Image courtesy of Gregory J. Czarnota

Receiver operator characteristics curve for the optimal response classifiers, optimized for maximum F1-Score. The AUCs for each classifier are reported in the legend. Image courtesy of Gregory J. Czarnota - [email protected]


August 6, 2021 — Oncotarget published "MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer" which reported that the authors investigated whether pre-treatment T2-weighted magnetic resonance imaging (MRI) can be used to predict response to neoadjuvant chemotherapy in breast cancer.

Response assessment was done using clinical-pathological responses with patients classified into binary groups: responders and non-responders.

Sevent features were significantly different between the two response groups. The best classification accuracy was obtained using a k-nearest neighbor model with sensitivity, specificity, accuracy, and area under curve of 63, 93, 87, and 0.78, respectively.

Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy.

Gregory J. Czarnota, M.D., from The Sunnybrook Health Sciences CentreThe University of Toronto as well as Ryerson University said, "Locally advanced breast cancer (LABC) is defined as breast cancer with tumors greater than 5 cm, primary disease involving the chest wall, skin, or advanced regional lymph node metastasis, without distant metastases."

Pathological response rates are worse, with approximately 20–40% of patients achieving pathological complete response. It would be helpful to develop imaging biomarkers to identify patients likely to benefit from NAC avoiding ineffective treatments in a selected cohort of patients having chemoresistant disease.

Radiomic analysis involving a wide range of imaging modalities, including magnetic resonance imaging, quantitative ultrasound, and computed tomography, has shown promising results in the assessment of clinical outcomes for patients with breast cancer.

In T2-weighted breast MRI, the texture of these images has been significantly correlated with pathological heterogeneity such that the texture could hypothetically be used to predict patient prognosis. The study examined T2 non-contrast images in predicting the treatment response to NAC.

The Czarnota Research Team concluded in their Oncotarget Research Output that one limitation of the current study was the use of different chemotherapy regimens. Additional texture features could be extracted from tumors using alternative methods of representation such as grey run-length matrices, grey-level size zone matrices, and first-order features, which will be included in future follow up studies. They intend to expand the current study cohort to include a higher number of patients to perform more robust validation strategies, including consideration of external validation from a different institution.

In comparison to other studies, these authors had used a different endpoint towards detection of chemotherapy response. They believe in clinical practice; it will be more prudent to continue NAC in patients demonstrating some or partial response rather than considering a stricter criterion of complete response.

For more information: www.oncotarget.com


Related Content

News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Artificial Intelligence

February 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered solutions that enable medical providers ...

Time February 28, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | PACS

February 22, 2024 — aycan, a recognized leader in medical imaging, announced that Enspectra Health used aycan’s PACS ...

Time February 22, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Subscribe Now